The Timing Hypothesis: When to Start HRT in Menopause

The timing hypothesis is the idea that *when* you start hormone therapy matters as much as *whether* you take it. Specifically, it proposes that starting HRT close to menopause—before age 60 or within about 10 years of your final period—offers the most benefit and the least risk, while starting it many years later may do more harm than good, especially for the heart.

This concept emerged from a puzzle. Early observational studies suggested HRT protected against heart disease, but the large Women's Health Initiative (WHI) trial in 2002 reported increased cardiovascular risk and was halted early. The contradiction confused doctors and frightened millions of women away from treatment.

The resolution came from looking at *who* was studied. The women in WHI were, on average, 63 years old—more than a decade past menopause for most. When researchers re-analyzed the data by age, a clearer picture emerged: younger women who started HRT near menopause did not show the same risks, and often showed benefits. That age-based pattern is the timing hypothesis.

The WHI made headlines in 2002 when it reported that combined estrogen-plus-progestin therapy raised the risk of heart disease, stroke, blood clots, and breast cancer. Hormone therapy prescriptions plummeted almost overnight, and a generation of women went without treatment for hot flashes, sleep disruption, and bone loss.

The problem wasn't that the data were wrong—it was that they were over-generalized. The trial enrolled mostly women in their 60s and 70s, many already years past menopause and at higher baseline cardiovascular risk. Applying those findings to a healthy 51-year-old with disruptive hot flashes was like judging a medication for one group based on results from a very different one.

Subsequent analyses, including the WHI 30-year follow-up, refined the message considerably. For women starting therapy in their 50s and near menopause, the absolute risks were small and the benefits—symptom relief, bone protection, and possibly cardiovascular benefit—were more favorable. Understanding this history helps explain why guidance today is far more nuanced than the 2002 headlines suggested. Our overview of [menopause and heart disease risk from the SWAN study](/blog/menopause-heart-disease-risk-what-swan-study-found) adds important context on why the menopause transition itself changes cardiovascular risk.

Two trials were designed specifically to test the timing hypothesis, and both support earlier initiation. The KEEPS trial (Kronos Early Estrogen Prevention Study) studied recently menopausal women and found that HRT started early improved menopausal symptoms, mood, and some markers of well-being, without harming the heart over the study period.

The ELITE trial (Early versus Late Intervention Trial with Estradiol, NEJM 2016) was even more direct. It randomized women into two groups—those within 6 years of menopause and those more than 10 years past it—and measured the progression of artery thickening. In the early group, estrogen slowed the buildup of atherosclerosis; in the late group, it did not. This was strong evidence that the same hormone can help or not depending on when it's started.

Together, KEEPS and ELITE reframed the conversation. Hormone therapy isn't inherently "risky" or "protective"—its effect depends heavily on the timing of initiation relative to menopause. That's a very different message from the fear that dominated the 2000s.

The timing window generally applies to women who are under 60 or within 10 years of their final period and who have bothersome menopausal symptoms or bone-loss concerns. For this group, major medical societies now consider the benefits of HRT to typically outweigh the risks, particularly for relieving hot flashes, night sweats, and vaginal symptoms and for protecting bone density.

That said, timing is one factor among several. Your personal and family history of breast cancer, blood clots, stroke, or liver disease all shape the decision, as do the type and route of hormones. Transdermal estrogen (patches and gels) carries a lower clot risk than oral estrogen, and if you have a uterus, progesterone is needed to protect the uterine lining. Our guides on [estrogen patch versus pill versus gel](/blog/estrogen-patch-vs-pill-vs-gel-which-hrt-is-right) and [progesterone in menopause](/blog/progesterone-in-menopause-what-it-does-and-why-it-matters) explain those choices.

Starting HRT much later—say, in your late 60s after a decade or more without hormones—requires a more cautious conversation, because the cardiovascular calculus shifts. It isn't automatically off the table, but the risk-benefit balance is different, and the decision should be individualized.

The decision to start HRT is personal and belongs in a conversation with a knowledgeable clinician—but the timing hypothesis gives you a useful framework. If you're in your late 40s or 50s, recently menopausal, and struggling with symptoms, you're squarely in the window where the evidence is most reassuring. Waiting "to be safe" isn't necessarily safer, and may mean years of unnecessary suffering plus lost bone.

Start by clarifying your goals. Are you chasing symptom relief, bone protection, or both? Then weigh your personal risk factors honestly with your provider. The North American Menopause Society and other bodies emphasize using the lowest effective dose for your needs and revisiting the decision periodically rather than treating it as permanent.

Menopause care has changed dramatically since 2002, and many women were told outdated information. If you were once turned away from HRT based on the old WHI headlines, it may be worth revisiting the question with current evidence in mind. And if bone health is part of your motivation, pair the conversation with our guide on [osteoporosis prevention in menopause](/blog/osteoporosis-prevention-menopause-protect-your-bones).